The immunogenicity and safety of GSK’s recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience

References

• World Health Organization. Hepatitis B vaccines: WHO position paper–recommendations. Vaccine. 2010;28:589–590.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health sector strategy on Viral hepatitis 2016–2021. Towards ending viral hepatitis, June 2016 (WHO/HIV/2016.06). Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
   Google Scholar
• Blumberg BS, Alter HJ, Visnich S. A “New” antigen in leukemia sera. JAMA. 1965;191:541–546.
   PubMed Web of Science ®Google Scholar
• Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain). Studies on active immunization. Jama. 1971;217:41–45.
   PubMed Web of Science ®Google Scholar
• Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204:39–55.
   PubMed Web of Science ®Google Scholar
• Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833–841.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Gray P, Quiroga M, et al. Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. Nature. 1979;280:815–819.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982;298:347–350.
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, et al. Human hepatitis B vaccine from recombinant yeast. Nature. 1984;307:178–180.
   PubMed Web of Science ®Google Scholar
• Expanded programme on immunization. Global Advisory Group–Part I. Wkly Epidemiol Rec. 1992;67:11–15. Epub 1992/01/17.
   PubMedGoogle Scholar
• Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266–6273.
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine. 2003;21:4626–4649.
   PubMed Web of Science ®Google Scholar
• Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179:489–492.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5:79–84.
   PubMedGoogle Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010;28:730–736.
   PubMed Web of Science ®Google Scholar
• ECDC. European centre for disease prevention and control. [ updated 2015 Jun 01]. Available from: http://www.ecdc.europa.eu/en/publications/surveillance_reports/Pages/index.aspx
   Google Scholar
• World Health Organization. [ cited 2016 Mar 21]. Available from: http://www.who.int/en/
   Google Scholar
• Centers for Disease Control and Prevention. [ cited 2016 Mar 21]. Available from: https://www.cdc.gov/
   Google Scholar
• Eurosurveillance 1996-2016. [ cited 2016 Mar 21]. Available from: http://www.eurosurveillance.org/
   Google Scholar
• EUROHEP.NET. [ cited 2016 Mar 21]. Available from: http://www.eurohep.net/
   Google Scholar
• Ayerbe MC, Perez-Rivilla A. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol. 2001;17:150–156. Epub 2001/10/16.
   PubMed Web of Science ®Google Scholar
• Vellinga A, Van Damme P, Weyler JJ, et al. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 1999;17:602–606. Epub 1999/03/13.
   PubMed Web of Science ®Google Scholar
• Chiaramonte M, Majori S, Ngatchu T, et al. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. Vaccine. 1996;14:135–137. Epub 1996/02/01.
   PubMed Web of Science ®Google Scholar
• Yang S, Tian G, Cui Y, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6:27251.
   PubMed Web of Science ®Google Scholar
• Harries AD, Clark M, Beeching NJ, et al. Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons. J Infect. 1991;23:251–254. Epub 1991/11/01.
   PubMed Web of Science ®Google Scholar
• Treadwell TL, Keeffe EB, Lake J, et al. Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med. 1993;95:584–588.
   PubMed Web of Science ®Google Scholar
• Bock HL, Kruppenbacher J, Sanger R, et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med. 1996;156:2226–2231. Epub 1996/10/28.
   PubMed Web of Science ®Google Scholar
• Levie K, Gjorup I, Skinhoj P, et al. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis. 2002;34:610–614. Epub 2002/09/20.
   PubMed Web of Science ®Google Scholar
• Moraes JC, Luna EJ, Grimaldi RA. Immunogenicity of the Brazilian hepatitis B vaccine in adults. Rev Saude Publica. 2010;44:353–359. Epub 2010/03/27.
   PubMed Web of Science ®Google Scholar
• Gilbert CL, Klopfer SO, Martin JC, et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin. 2011;7:1336–1342. Epub 2011/12/22.
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine. 2012;30:2689–2696. Epub 2012/02/22.
   PubMed Web of Science ®Google Scholar
• Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. Vaccine. 2013;31:5300–5305. Epub 2013/06/04.
   PubMed Web of Science ®Google Scholar
• Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol. 2013;58:262–264. Epub 2013/07/31.
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Kundi M, Stemberger H, et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine. 2001;19:2055–2060. Epub 2001/03/03.
   PubMed Web of Science ®Google Scholar
• Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine. 2001;19:4710–4719.
   PubMed Web of Science ®Google Scholar
• Van Der Wielen M, Van Damme P, Chlibek R, et al. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24:5509–5515. Epub 2006/05/27.
   PubMed Web of Science ®Google Scholar
• Martins RM, Bensabath G, Arraes LC, et al. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz. 2004;99:865–871. Epub 2005/03/12.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28:3595–3601. Epub 2010/03/02.
   PubMed Web of Science ®Google Scholar
• Wang H, Cai B, Rao D, et al. Rapid immunization effects of a new type of 60 µg hepatitis B vaccine compared with traditional 20 µg hepatitis B vaccines in adults. Hum Vaccin Immunother. 2016;12:2921–2926.
   PubMed Web of Science ®Google Scholar
• Young MD, Rosenthal MH, Dickson B, et al. A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine. Vaccine. 2001;19:3437–3443. Epub 2001/05/12.
   PubMed Web of Science ®Google Scholar
• Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine. 2002;20:1157–1162.
   PubMed Web of Science ®Google Scholar
• Connor BA, Blatter MM, Beran J, et al. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med. 2007;14:9–15. Epub 2007/01/24.
   PubMed Web of Science ®Google Scholar
• Rodrigo JM, Serra MA, Aparisi L, et al. Immune response to hepatitis B vaccine in parenteral drug abusers. Vaccine. 1992;10:798–801. Epub 1992/01/01.
   PubMed Web of Science ®Google Scholar
• Rustgi VK, Schleupner CJ, Krause DS. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine. 1995;13:1665–1668. Epub 1995/12/01.
   PubMed Web of Science ®Google Scholar
• Bock HL, Loscher T, Scheiermann N, et al. Accelerated schedule for hepatitis B immunization. J Travel Med. 1995;2:213–217. Epub 1995/12/01.
   PubMedGoogle Scholar
• Averhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1–8. Epub 1998/07/04.
   PubMed Web of Science ®Google Scholar
• Knoll A, Hottentrager B, Kainz J, et al. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine. 2000;18:2029–2032. Epub 2000/03/09.
   PubMed Web of Science ®Google Scholar
• Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol. 1994;10:541–547. Epub 1994/10/01.
   PubMed Web of Science ®Google Scholar
• Rogan PD, Duguid JK. Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine. J Infect. 1991;22:5–9. Epub 1991/01/01.
   PubMed Web of Science ®Google Scholar
• Zeeshan M, Jabeen K, Ali AN, et al. Evaluation of immune response to hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. BMC Infect Dis. 2007;7:120. Epub 2007/10/27.
   PubMed Web of Science ®Google Scholar
• Hess G, Hingst V, Cseke J, et al. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur J Clin Microbiol Infect Dis. 1992;11:334–340. Epub 1992/04/01.
   PubMed Web of Science ®Google Scholar
• Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines. 2007;6:133–140.
   PubMed Web of Science ®Google Scholar
• Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1–43.
   PubMedGoogle Scholar
• Fernandez E, Betriu MA, Gomez R, et al. Response to the hepatitis B virus vaccine in haemodialysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant. 1996;11:1559–1563. Epub 1996/08/01.
   PubMed Web of Science ®Google Scholar
• Sorkhi H, Roushan MR, Al Hashemi GH, et al. Response to hepatitis B virus vaccination in haemodialysis patients with and without hepatitis C infection. East Mediterr Health J. 2008;14:798–803. Epub 2009/01/27.
   PubMedGoogle Scholar
• Hashemi B, Mahdavi-Mazdeh M, Abbasi M, et al. Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better? Hepat Mon. 2011;11:816–820. Epub 2012/01/10.
   PubMed Web of Science ®Google Scholar
• Peces R, De La Torre M, Alcazar R, et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis. 1997;29:239–245. Epub 1997/02/01.
   PubMed Web of Science ®Google Scholar
• Fleming SJ, Moran DM, Cooksley WG, et al. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect. 1991;22:251–257. Epub 1991/05/01.
   PubMed Web of Science ®Google Scholar
• Rault R, Freed B, Nespor S, et al. Efficacy of different hepatitis B vaccination strategies in patients receiving hemodialysis. Asaio J. 1995;41:M717–719. Epub 1995/07/01.
   PubMedGoogle Scholar
• Sezer S, Ozdemir FN, Guz G, et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc. 2000;32:607–608. Epub 2000/05/17.
   PubMed Web of Science ®Google Scholar
• Bel’eed K, Wright M, Eadington D, et al. Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J. 2002;78:538–540. Epub 2002/10/03.
   PubMed Web of Science ®Google Scholar
• Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68:2298–2303. Epub 2005/10/14.
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JH, Lin CC, et al. Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients. Vaccine. 2011;29:3738–3741. Epub 2011/04/05.
   PubMed Web of Science ®Google Scholar
• Nahar K, Jahan M, Nessa A, et al. Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients. Bangladesh Med Res Counc Bull. 2011;37:88–91. Epub 2012/02/23.
   PubMedGoogle Scholar
• Gilbert CL, Stek JE, Villa G, et al. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients. Vaccine. 2014;32:6521–6526. Epub 2014/09/25.
   PubMed Web of Science ®Google Scholar
• Janssen JM, Heyward WL, Martin JT, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. Vaccine. 2015;33:833–837. Epub 2015/01/13.
   PubMed Web of Science ®Google Scholar
• Garcia-Agudo R, Aoufi Rabih S, Araque Torres P, et al. Efficacy of a hepatitis B vaccination schedule with two cycles of four double doses of conventional vaccine and four doses of adjuvanted vaccine in chronic kidney disease patients evaluated for renal transplantation. Transplant Proc. 2012;44:2532–2534. Epub 2012/11/14.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Peterson JT, Dionne M, et al. Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Hum Vaccin Immunother. 2016;8:2197–2203.
   Web of Science ®Google Scholar
• Arslan M, Wiesner RH, Sievers C, et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001;7:314–320. Epub 2001/04/17.
   PubMed Web of Science ®Google Scholar
• Feng L, Niu Y, Chen H, et al. Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients. Hepatol Res. 2013;43:495–501. Epub 2012/11/20.
   PubMed Web of Science ®Google Scholar
• Dominguez M, Barcena R, Garcia M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl. 2000;6:440–442. Epub 2000/07/29.
   PubMed Web of Science ®Google Scholar
• De Maria N, Idilman R, Colantoni A, et al. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis. J Viral Hepat. 2001;8:372–376. Epub 2001/09/14.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Menchen L, Garcia-Sanchez V, et al. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379–1385. Epub 2012/04/26.
   PubMed Web of Science ®Google Scholar
• Belle A, Baumann C, Bigard MA, et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2015;27:877–881. Epub 2015/06/30.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1460–1466. Epub 2012/10/05.
   PubMed Web of Science ®Google Scholar
• Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr. 2011;56:325–332.
   PubMed Web of Science ®Google Scholar
• Fonseca MO, Pang LW, De Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902–2908. Epub 2005/03/23.
   PubMed Web of Science ®Google Scholar
• Pollack TM, Trang LTT, Ngo L, et al. Response to hepatitis B vaccination among HIV-infected adults in Vietnam. J Virus Erad. 2016;2:102–106.
   PubMed Web of Science ®Google Scholar
• Sodhi JS, Raja W, Zargar SA, et al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy. Indian J Gastroenterol. 2015;34:372–379. Epub 2015/11/05.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Vranckx R, Meheus A. Immunogenicity of a recombinant DNA hepatitis B vaccine in institutionalized patients with Down’s syndrome. Vaccine. 1990;8 Suppl:S53–55. discussion S60-52. Epub 1990/03/01.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Vranckx R, Safary A, et al. Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients. Am J Med. 1989;87:26s–29s. Epub 1989/09/04.
   PubMed Web of Science ®Google Scholar
• Tran TQ, Grimes CZ, Lai D, et al. Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users. Vaccine. 2012;30:342–349. Epub 2011/11/15.
   PubMed Web of Science ®Google Scholar
• Wouters K, Leuridan E, Herck K, et al. Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium. Vaccine. 2007;25:1893–1900.
   PubMed Web of Science ®Google Scholar
• Rosman AS, Basu P, Galvin K, et al. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med. 1997;103:217–222. Epub 1997/10/08.
   PubMed Web of Science ®Google Scholar
• Motta-Castro AR, Gomes SA, Yoshida CF, et al. Compliance with and response to hepatitis B vaccination in remaining quilombo communities in Central Brazil. Cad Saude Publica. 2009;25:738–742. Epub 2009/04/07.
   PubMed Web of Science ®Google Scholar
• Gupta I, Ratho RK. Immunogenicity and safety of two schedules of hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res. 2003;29:84–86. Epub 2003/05/21.
   PubMed Web of Science ®Google Scholar
• Bayas JM, Bruguera M, Martin V, et al. Hepatitis B vaccination in prisons: the Catalonian experience. Vaccine. 1993;11:1441–1444. Epub 1993/11/01.
   PubMed Web of Science ®Google Scholar
• Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix(R) or HBVaxPro(R) results in better response rates than does revaccination with three doses of Engerix-B(R) in previous non-responders. Vaccine. 2012;30:6734–6737. Epub 2012/09/18.
   PubMed Web of Science ®Google Scholar
• Desombere I, Van Der Wielen M, Van Damme P, et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine. 2002;20:2597–2602. Epub 2002/06/12.
   PubMed Web of Science ®Google Scholar
• Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.
   PubMed Web of Science ®Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021–1051.
   PubMed Web of Science ®Google Scholar
• Van Der Meeren O, Crasta P, Cheuvart B, et al. Characterization of an age-response relationship to GSK’s recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccin Immunother. 2015;11:1726–1729.
   PubMed Web of Science ®Google Scholar
• Ni JD, Xiong YZ, Wang XJ, et al. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24:117–122.
   PubMed Web of Science ®Google Scholar
• Lu PJ, Byrd KK, Murphy TV, et al. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. Vaccine. 2011;29:7049–7057.
   PubMed Web of Science ®Google Scholar
• Ascherio A, Zhang SM, Hernán MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med. 2001;344:327–332.
   PubMed Web of Science ®Google Scholar
• DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504–509.
   PubMedGoogle Scholar
• Ramagopalan SV, Valdar W, Dyment DA, et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology. 2009;32:257–262.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Suissa S, Saddier P, et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med. 2001;344:319–326.
   PubMed Web of Science ®Google Scholar
• Stramer SL, Wend U, Candotti D, et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med. 2011;364:236–247.
   PubMed Web of Science ®Google Scholar
• Cassidy A, Mossman S, Olivieri A, et al. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity. Expert Rev Vaccines. 2011;10:1709–1715.
   PubMed Web of Science ®Google Scholar
• Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity. Lancet. 2000;355:561–565.
   PubMed Web of Science ®Google Scholar